Collegium Pharmaceutical Stock Price - COLL

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
After Hours
Last Trade
Last $ 20.40 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Collegium Pharmaceutical Inc COLL NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.83 -3.91% 20.40 21.39 20.38 21.36 21.23 16:30:00
Bid Price Ask Price Spread Spread % News
19.33 22.00 2.67 12.14% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,823 234,552 $ 20.94 $ 4,911,308 571,006 10.01 - 22.28
Last Trade Time Type Quantity Stock Price Currency
16:44:21 formt 11,689 $ 20.40 USD

Collegium Pharmaceutical Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 689.65M 33.53M $ -39.13M -1.20 -63.72 32.77M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 2.30%

more financials information »

Collegium Pharmaceutical News

Loading Messages....

Latest COLL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical COLL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week21.0821.5020.2520.82248,617-0.68-3.23%
1 Month18.7222.2817.7020.05373,6951.688.97%
3 Months12.1122.2810.42515.68433,9558.2968.46%
6 Months11.8222.2810.0113.97346,7838.5872.59%
1 Year19.3222.2810.0114.71376,4331.085.59%
3 Years16.2029.907.3716.38456,2064.2025.93%
5 Years12.0030.587.3716.50363,7758.4070.0%

Collegium Pharmaceutical Description

Collegium Pharmaceutical Inc is a US-based specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. The company's product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.


Your Recent History
NASDAQ
COLL
Collegium ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.